Acute Myeloid Leukemia (AML): Sufferers with AML often exhibit substantial CD47 expression, which correlates with intense disease progression and inadequate prognosis. Nadecnemab has proven efficacy in enhancing immune recognition and destruction of leukemic cells, resulting in improved therapy responses. Nadecnemab is undoubtedly an IgG4κ antibody focusing on to GFRA3, glial https://johnnieu616caz8.wikibestproducts.com/user